Premium
Preparation of bismuth sulfide nanoparticles as targeted biocompatible nano‐radiosensitizer and carrier of methotrexate
Author(s) -
Azizi Sedigheh,
Nosrati Hamed,
Sharafi Ali,
Danafar Hossein
Publication year - 2020
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.5251
Subject(s) - chemistry , biocompatibility , bovine serum albumin , carbodiimide , nuclear chemistry , zeta potential , cytotoxicity , nanoparticle , mtt assay , in vivo , radiosensitizer , in vitro , nanotechnology , biochemistry , organic chemistry , materials science , medicine , microbiology and biotechnology , biology , radiation therapy
In this study, Bi 2 S 3 @BSA–Bio–MTX nanoparticles (NPs) were synthesized for the first time by bovine serum albumin (BSA)‐mediated biomineralization (Bi 2 S 3 @BSA NPs) followed by covalent bonding of biotin (Bio) and methotrexate (MTX) on the surface of the Bi 2 S 3 @BSA NPs via carbodiimide chemistry. The synthesized NPs were globular and exhibited uniform morphology with a hydrodynamic diameter of 107.6 ± 6.81 nm (mean ± standard deviation) and zeta potential of −20.9 ± 2.18 mV. Drug release from Bi 2 S 3 @BSA–Bio–MTX NPs indicated an enzyme‐dependent release pattern. The in vitro biocompatibility of NPs was confirmed by investigating their cytotoxicity against the HEK‐293 cell line and hemolysis assay test, whereas the in vivo biocompatibility of the NPs was evaluated and confirmed by the lethal dose 50 (LD 50 ) test. To evaluate the in vitro anticancer activity of the functionalized NPs and MTX, their cytotoxic effects was assessed against 4T1 cancer cells by 5‐dimethylthiazol‐z‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay with and without X‐ray radiation. Results showed that Bi 2 S 3 @BSA–Bio–MTX NPs have excellent anticancer activity, especially following X‐ray radiation.